

Food and Drug Administration

FY 2023 Operating Plan Narrative

Overview: On December 29, 2022, the President signed the Consolidated Appropriations Act, 2023 (P.L. 117-328). The FY 2023 appropriation provides a total program level of \$6.7 billion to FDA, which is an increase of \$470.0 million over FY 2022. This total includes \$3.6 billion in budget authority, which is a net increase of \$226.0 million over FY 2022. This also includes \$3.1 billion for user fees and \$50.0 million of 21st Century Cures funding.

Changes Compared to FY 2022 Enacted:

Infrastructure – increase of \$21.1 million for FDA Infrastructure:

- +\$1.8 million for FDA White Oak Complex
- +\$19.3 million for Other Rent and Rent Related

Crosscutting – increases of \$121.1 million for Crosscutting activities:

- +\$15.0 million for Data Modernization Enterprise-Wide Technology and Data
- +\$10.0 million for Inspections
- +\$71.1 million for Pay Costs
- +\$2.5 million for the Office of Minority Health and Health Equity
- +\$1.5 million for Laboratory Safety
- +\$2.5 million for Office of the Chief Counsel
- +\$13.5 million for Essential Services
- +\$5.0 million for the Reducing Animal Testing Through Alternative Methods initiative

Food Safety – increases of \$41.0 million for Food Safety activities:

- +\$20.0 million for the New Era of Smarter Food Safety
- +\$10.0 million for Maternal and Infant Health and Nutrition
- +\$8.0 million for Emerging Chemical and Toxicological Issues
- +\$1.0 million for Standards of Identity
- +\$1.0 million for Sodium
- +\$1.0 million for Shrimp Import Learning

Medical Product Safety – increases of \$42.8 million for Medical Product Safety activities:

- +\$5.0 million for Shortages & Supply Chain
- +\$0.8 million for Animal Medical Product Supply Chain
- +\$7.0 million for Advancing the Goal of Ending the Opioid Crisis
- +\$3.0 million for Predictive Toxicology Roadmap
- +\$5.0 million for Data Modernization and Enhanced Technologies
- +\$1.5 million for Drug Safety Surveillance and Oversight
- +\$5.0 million for Premarket Animal Drug Review Workload
- +\$5.0 million for Medical Device Cybersecurity

- +\$2.0 million for Cancer Moonshot
- +\$5.0 million for the ACT for ALS
- +\$1.5 million Foreign Inspections Pilot
- +\$2.0 million for the Neurology Drug Program